Compare CNVS & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNVS | LUNG |
|---|---|---|
| Founded | 2000 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Video Chains | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.7M | 57.9M |
| IPO Year | 2016 | 2020 |
| Metric | CNVS | LUNG |
|---|---|---|
| Price | $2.90 | $1.26 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $9.00 | $5.38 |
| AVG Volume (30 Days) | 119.3K | ★ 364.8K |
| Earning Date | 02-17-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 108.99 | 7.64 |
| EPS | N/A | ★ N/A |
| Revenue | $78,181,000.00 | ★ $90,497,000.00 |
| Revenue This Year | N/A | $2.48 |
| Revenue Next Year | $84.42 | $18.46 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 59.13 | 8.01 |
| 52 Week Low | $1.77 | $1.13 |
| 52 Week High | $7.39 | $3.88 |
| Indicator | CNVS | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 64.12 | 37.02 |
| Support Level | $2.34 | $1.19 |
| Resistance Level | $2.93 | $1.67 |
| Average True Range (ATR) | 0.18 | 0.11 |
| MACD | 0.05 | -0.04 |
| Stochastic Oscillator | 58.07 | 7.07 |
Cineverse Corp is a main streaming technology and entertainment company. Its core business operates as a portfolio of owned and operated streaming channels with enthusiast fan bases; a large-scale aggregator and full-service distributor of feature films and television programs; and a proprietary technology software-as-a-service platform for over-the-top (OTT) app development and content distribution through subscription video-on-demand (SVOD), dedicated ad-supported (AVOD), ad-supported streaming linear (FAST) channels, social video streaming services, and audio podcasts. It generates revenue from streaming and digital, Base distribution, Podcast and other, and Other non-recurring.
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.